In-The-Know
GLP-1 List Prices and the Real Cost to Your Plan
In this issue
On January 1, 2027, Novo Nordisk will reduce its list prices for Wegovy, Ozempic, and Rybelsus to $675 a month. This represents an approximate 50% reduction for Wegovy and a 35% reduction for Ozempic.
This announcement raises two related but distinct questions for employer-sponsored plans:
First, how does list price relate to what a plan actually pays? The $675 figure is a Wholesale Acquisition Cost (WAC) — a published list price before discounts, rebates, or other contract adjustments. Net cost can look very different.
Second, will this specific price reduction lower employer plan costs in 2027? That is not guaranteed, and clients may need help understanding why.
For consultants, the central message is this: a significant reduction in list price does not automatically translate into an equivalent reduction in plan spend. Helping clients understand the distinction — and then quantifying the effect under their specific PBM contract — should be an important part of 2027 pharmacy planning conversations.
Start by Separating List Price from Plan Cost
A useful first step is making sure clients understand that the $675 figure is the list price. Understanding the distinction between list price and net cost will equip you to guide that conversation and help clients avoid building budgets around a headline price that may not reflect what the plan actually pays.
Wholesale Acquisition Cost (WAC) is the manufacturer’s published list price before any discounts, rebates, or incentives are applied. It is often the figure cited in public-facing headlines (e.g., "Novo Nordisk lowers list price to $675"). WAC can affect member cost sharing in benefit designs where deductibles or coinsurance are tied to a drug’s negotiated or list price.
WAC should not be treated as synonymous with an employer’s net pharmacy cost. For employer-sponsored plans, the ultimate cost can reflect negotiated ingredient pricing, manufacturer rebates and other payments, member cost sharing, PBM guarantees, administrative fees, and other provisions in the PBM contract. Relying on list prices to forecast a budget is akin to predicting the price of a car based solely on the MSRP without accounting for dealer incentives, trade-ins, or fleet discounts.
Net Cost (The "Real Price") is the final amount an employer pays for a drug after all PBM-negotiated financial adjustments are taken into account.
Consider a simplified illustration:
A drug costs $1,000 with a $400 rebate has a net cost of $600 before considering other contract terms. If the manufacturer drops the list price to $675 while the corresponding rebate falls substantially, the plan’s net cost might decline only modestly or remain near its previous cost. Though the numbers will differ by client, the principle is the same. Consultants should model the net economics.
Why This Matters when it comes to GLP-1
GLP-1 utilization continues to be an important cost and benefit management issue for employer-sponsored plans, and a price change of this magnitude is precisely the kind of development clients are likely to question. They will want to understand whether the announced pricing change affects their budget, plan design, or negotiating position with their pharmacy benefit manager (PBM) for 2027. It is a timely opportunity to lead the conversation rather than respond to it.
What Is Actually Changing on January 1, 2027
The new $675 monthly list price does not affect direct-to-consumer self-pay pricing programs. Whether the WAC reduction lowers what employers actually pay is a separate question. Mercer and WTW have both cautioned that the reduction in list price may not materially affect net price. That does not mean every employer will experience the same outcome. It means consultants should verify the impact using each client’s specific contract and claims data rather than assuming that a 35% or 50% reduction in WAC will translate into an equivalent reduction in plan cost.
The effect may be most visible to employees rather than employers. Members who pay coinsurance rather than a flat copay may see reduced out-of-pocket costs at the pharmacy counter, since coinsurance is calculated against list price. At the same time, if manufacturer rebates decline, the employer’s net total cost may not fall proportionately. This shift can go unnoticed without close attention to plan design.
How You Can Help Your Clients Prepare
- Start with the data and establish a baseline. Request a claims breakdown from the PBM that identifies unique utilizers, separates GLP-1 use by drug and indication, gross ingredient cost, rebates and other applicable contractual credits, and estimated net plan cost. Separating utilization from unit cost is important. Use that baseline to inform every subsequent decision.
- Go back to the PBM contract before drawing conclusions. Ask directly how the list price change affects any rebate guarantees, drug-specific versus aggregate guarantees, formulary placement or guarantees, pricing definitions, treatment of manufacturer price changes, administrative fees, and net cost projections under the client's specific contract. A pass-through arrangement will respond differently than a traditional spread-pricing contract, and the difference can be substantial at scale. An independent audit or market check can provide additional validation. The objective is to ensure the client’s financial expectations can be reconciled to the terms of the contract.
- Model cost-share and review plan design. Evaluate how the lower list price affects member out-of-pocket cost and plan net cost. Those two numbers may not move in parallel. In some arrangements, members subject to deductibles or coinsurance may experience lower out-of-pocket costs. At the same time, lower manufacturer rebates could mean that the employer’s net cost declines less. That makes benefit design important.
- Revisit your client’s broader GLP-1 strategy. Review the client’s approach to GLP-1 coverage including: eligibility requirements, prior authorization criteria, step therapy requirements, member engagement and lifestyle-support programs, adherence strategies, and whether coverage extends beyond diabetes to weight management. Consider asking what is the most clinically responsible and financially sustainable GLP-1 strategy for this client’s population?
- Examine stop-loss contract language. Review how pharmacy claims are treated under the plan's stop-loss coverage. That does not mean an individual GLP-1 prescription will necessarily generate a specific stop-loss claim. Rather, the review should determine whether pharmacy claims are included in aggregate and/or specific claim calculations, what exclusions apply, how PBM rebates or credits are treated, and whether the medical and pharmacy programs are integrated appropriately for stop-loss reporting.
- Prepare clients for employee questions. GLP-1 medications are heavily marketed directly to consumers, and employees will have questions about what is changing. Consultants can help clients prepare concise communications explaining plan coverage, member cost sharing, and if authorization requirements are changing to reduce confusion and limit informal inquiries to HR.
Looking Ahead
GLP-1 pricing and competition are evolving faster than at any point in the drug class's history, and January 1, 2027, does not mark an endpoint. Additional products, new distribution models, changing manufacturer strategies, and greater competition could continue to reshape both pricing and employer coverage decisions. Employers best positioned for 2027 will be those whose consultant helped them understand their current utilization and contract terms, established their true net cost, modeled impact, and created a process for revisiting those assumptions as the market changes.
For a deeper dive on building a sustainable GLP-1 strategy, listen to Health Action Council's podcast episode, Listening Through the GLP-1 Noise: A Strategy for Sustainability, featuring Kelly Chillingworth of Integrity RX Partners.